Меланома и рак кожи

Прорыв в лечении рака кожи: мРНК-вакцина на 42% снизила риск возвращения меланомы

Прорыв в лечении рака кожи: мРНК-вакцина на 42% снизила риск возвращения меланомы Vesti Ua

Personalised cancer vaccine with immunotherapy cuts risk of melanoma returning by 42%, study finds

Personalised cancer vaccine with immunotherapy cuts risk of melanoma returning by 42%, study finds The Pharmaceutical Journal

Patient welcomes “groundbreaking” skin cancer vaccine trial results

Patient welcomes “groundbreaking” skin cancer vaccine trial results Cambridge University Hospitals

TIL Therapy Plus Pembrolizumab for Advanced Melanoma

TIL Therapy Plus Pembrolizumab for Advanced Melanoma The ASCO Post

Family melanoma-prevention program improves sun-safety habits, not child sunburns

A melanoma intervention for survivors and their families improved sun-protection behaviors but did not reduce child sunburn incidence over time, according to a study published in JAMA Dermatology. The family, lifestyles, actions and risk education intervention, known as FLARE, is a telehealth program that educated…

Вакцина против меланомы снизила риск рецидива и смерти на 42%: результаты испытаний удивили ученых

Вакцина против меланомы снизила риск рецидива и смерти на 42%: результаты испытаний удивили ученых bigmir)net

Melanoma and Skin Cancer Data You May Have Missed at ESMO 2026

Cancer Vaccine Could Boost Melanoma Survival, Trial Finds

Cancer Vaccine Could Boost Melanoma Survival, Trial Finds U.S. News & World Report

Tumours vanish in nearly one in three patients in advanced melanoma trial

Tumours vanish in nearly one in three patients in advanced melanoma trial The Institute of Cancer Research (ICR)

Positive Melanoma mRNA Vaccine Trial Data Sparks Personalized Medicine Hope

Positive Melanoma mRNA Vaccine Trial Data Sparks Personalized Medicine Hope The Scientist

Q&A: Could a new melanoma vaccine change cancer treatment?

A personalized melanoma vaccine, called intismeran, could mark a major advance in cancer treatment. Last week, pharmaceutical companies Merck and Moderna announced clinical trial results showing the vaccine, combined with immunotherapy, reduced the risk of cancer returning or death by 42% compared with immunotherapy…

Encorafenib/Binimetinib Plus Pembrolizumab Extends PFS in BRAF V600 Melanoma

ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine

ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine Clinical Trials Arena

Кандидат Merck и Moderna снизил риск рецидива меланомы на 42%

Кандидат Merck и Moderna снизил риск рецидива меланомы на 42% the Pharma Media

Первая в мире вакцина против рака превзошла ожидания учёных: риск возвращения меланомы снизился на 42% - Поиск

Первая в мире вакцина против рака превзошла ожидания учёных: риск возвращения меланомы снизился на 42% Поиск - новости науки и техники